If MSCs are administered too early in pre-clinical models of acute GvHD, they fail to dampen the GvHD response as levels of the pro-inflammatory cytokine IFN-γ, which is known to activate MSC immunomodulatory function, are too low (71, 72). This evidence concerns the gene IFNG and graft versus host disease.